524414
NORRIS
Start SIP
Invest Now
Start SIP in NORRIS
Performance
- Low
- ₹15
- High
- ₹16
- 52 Week Low
- ₹14
- 52 Week High
- ₹25
- Open Price₹15
- Previous Close₹16
- Volume1,193
Investment Returns
- Over 1 Month + 6%
- Over 3 Month -1%
- Over 6 Month -12.35%
- Over 1 Year -8.36%
Smart Investing Starts Here Start SIP with Norris Medicines for Steady Growth!
Norris Medicines Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -10.3
- PEG Ratio
- 0.1
- Market Cap Cr
- 16
- P/B Ratio
- -1
- Average True Range
- 1.08
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0.14
- RSI
- 49.84
- MFI
- 75.83
Norris Medicines Financials
Norris Medicines Technicals
EMA & SMA
Current Price
₹15.90
-0.05
(-0.31%)
- Bearish Moving Average 13
- Bullish Moving Average 3
- 20 Day
- ₹15.96
- 50 Day
- ₹15.94
- 100 Day
- ₹16.27
- 200 Day
- ₹16.80
Resistance and Support
15.49
- R3 17.75
- R2 16.86
- R1 16.38
- S1 15.01
- S2 14.12
- S3 13.64
Norris Medicines Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-14 | Quarterly Results | |
| 2025-08-14 | Quarterly Results | |
| 2025-05-28 | Audited Results | |
| 2025-02-13 | Quarterly Results & Others | Inter-alia, to consider 1. Requests from Mr. Nimish Bhishma Thakore, for reclassification from Promoter / Promoter Group into Public Category. 2. Other business matters. |
| 2024-11-14 | Quarterly Results |
Norris Medicines F&O
About Norris Medicines
- NSE Symbol
- NORRIS
- BSE Symbol
- 524414
- ISIN
- INE744C01029
Similar Stocks to Norris Medicines
Norris Medicines FAQs
Norris Medicines share price is ₹15 As on 01 January, 2026 | 19:53
The Market Cap of Norris Medicines is ₹15.9 Cr As on 01 January, 2026 | 19:53
The P/E ratio of Norris Medicines is -10.3 As on 01 January, 2026 | 19:53
The PB ratio of Norris Medicines is -1 As on 01 January, 2026 | 19:53
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.